米菲普里斯通过NRF2/GSH/GST介导的铁灭抑制来保护亚美诺芬诱导的肝损伤
Yanyun Shi1, Nahua Xu2, Baiping Liu3
1GuiZhou University Medical College, Guiyang, 550025, China.
Free radical biology & medicine
|June 21, 2024
概括
米费普里斯 (RU486) 抑制铁亡,这是一种细胞死亡途径,与药物诱导的肝损伤等疾病有关. 它激活了涉及谷氨和NRF2的独立解毒途径,提供了潜在的治疗策略.
科学领域:
- 生物化学 生物化学
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 铁亡是一种依赖于铁的细胞死亡机制,与药物诱导性肝损伤 (DILI) 等疾病相关.
- 现有的研究已经确定了几种对抗铁亡的途径,包括xCT/GSH/GPX4和FSP1/CoQ10.
- 发现新的抗铁灭菌路径对于理解铁灭菌和开发新的治疗药物至关重要.
研究的目的:
- 确定新的铁灭抑制剂并阐明它们的作用机制.
- 为了研究米费普里斯 (RU486) 作为铁灭抑制剂的潜力.
- 在药物诱导的肝损伤的小鼠模型中探索RU486的治疗疗效.
主要方法:
- 在体外基于细胞的试验以评估RU486.6的ferroptosis抑制.
- 涉及谷氨 (GSH) 合成,排毒酶 (GSTs) 和载体蛋白的机制研究 (RLIP76,MRP1).
- 在活体研究中,使用小鼠模型进行了乙氨基 (APAP) 诱导的急性肝损伤.
主要成果:
- 米费普里斯 (RU486) 被确定为一种新的铁灭抑制剂.
- RU486通过诱导GSH合成和激活NRF2通路而起作用,从而提高了像4-HNE这样有害的副产品的排毒.
- 这种RU486介导的抗铁灭菌通路,涉及GSH/GST/RLIP76&MRP1,独立于以前已知的铁灭菌防御系统运作.
- 在APAP诱导的肝损伤小鼠模型中,RU486显示出显著的肝保护作用,减少肝损伤标志物和氧化应激.
结论:
- RU486是一种新的铁灭抑制剂,通过独立的NRF2/GSH/GST/RLIP76&MRP1介导的解毒途径起作用.
- 这一途径为治疗ferroptosis相关疾病的治疗干预提供了一个新的目标.
- RU486显示为一种有前途的保护剂,可以防止药物诱导的肝损伤.
更多相关视频
相关概念视频
Hepatic Drug Excretion: Enterohepatic Cycling
1.5K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
1.5K
Regulation of the Unfolded Protein Response
2.4K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.4K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
403
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
403
Transducer Mechanism: Nuclear Receptors
1.3K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.3K
The Unfolded Protein Response
4.5K
The ER is the hub of protein synthesis in a cell. It has robust systems to quality control protein folding and also for degradation of terminally misfolded proteins. Under normal conditions, a small proportion of misfolded proteins that cannot be salvaged need to be transported to the cytoplasm by the ER-associated degradation or ERAD pathways. However, if the ERAD cannot handle the misfolded proteins, the cell activates the unfolded protein response or UPR to adjust the protein folding...
4.5K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
517
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
517


